For Investigational Anticancer Agent E7777 for U.S, Europe and certain Emerging Markets
Dr Reddys Laboratories announced that it has entered into a licensing agreement with Eisai Co., Japan by which Dr Reddy's will be granted exclusive worldwide development and commercialisation rights (excluding Japan and Asia) For Eisai's investigational anticancer agent E7777. Eisai will be responsible for the development and marketing of E7777 in Japan and Asia, while Dr Reddy's holds the option for rights to develop and market the agent in India.Powered by Capital Market - Live News
